Briz Verónica, Poveda Eva, Soriano Vicente
Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Spain.
Med Clin (Barc). 2006 Mar 11;126(9):341-8. doi: 10.1157/13085735.
Human immunodeficiency virus (HIV) entry into cells is the first step in the viral replication cycle, which has been explored as a new therapeutic target. A better knowledge of the mechanisms involved in the entry process has led to the development of agents, which may inhibit each of the different steps of the viral entry process: attachment of the gp120 to the CD4 cell receptor; binding of the gp120 to CCR5 or CXCR4 coreceptors; and the fusion of viral and cell membranes. Entry inhibitors are the latest family of antiretroviral compounds, being enfuvirtide, a fusion inhibitor, the first approved. Several other entry inhibitors are currently in clinical development and hopefully soon will be part of the therapeutic armamentarium against HIV.
人类免疫缺陷病毒（HIV）进入细胞是病毒复制周期的第一步，这已被作为一个新的治疗靶点进行研究。对病毒进入过程中涉及的机制有了更深入的了解，促使了一些药物的研发，这些药物可能会抑制病毒进入过程的各个不同步骤：gp120与CD4细胞受体的结合；gp120与CCR5或CXCR4共受体的结合；以及病毒膜与细胞膜的融合。进入抑制剂是最新一类抗逆转录病毒化合物，恩夫韦肽作为一种融合抑制剂是首个被批准的药物。目前还有其他几种进入抑制剂正在进行临床开发，有望很快成为对抗HIV的治疗手段之一。
